Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05440747 | Treatment Free Remission (TFR) in CML Patients (CML-CP)Study | not yet recruiting | — | 203 | Guangdong Provincial People's HospitalOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 |
| clinicaltrials |
| NCT05161026 | Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry(REMODALLO) | not yet recruiting | N/A | 120 | University Hospital, CaenOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04451200 | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning(BUSEQ) | not yet recruiting | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 1, 2022source: clinicaltrials